Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) has issued a notice convening its 2026 Second H Shareholders Class Meeting, to be held immediately after the Annual General Meeting and the concurrent A Shareholders Class Meeting on Tuesday, 16 June 2026, at the Sky Fortune Boutique Hotel Shanghai.
Key agenda items:
1. General mandate to repurchase up to 10% of issued H shares • The Board is seeking authority to buy back up to 10% of the company’s issued H shares (excluding treasury shares) during the “Relevant Period,” defined as the interval from shareholders’ approval on 16 June 2026 until either the next AGM or an earlier revocation/variation by shareholders. • Repurchased shares may be cancelled or retained as treasury shares, with consequent adjustments to registered capital and the Articles of Association. • Execution is contingent on parallel approval of identical resolutions at the AGM, the A Shareholders Class Meeting and by any required regulatory bodies.
2. General mandate to repurchase up to 10% of issued A shares • The Board seeks a similar 10% buyback capacity for A shares via centralised bidding, applicable during the same Relevant Period. • Permitted purposes include employee share ownership or equity incentive schemes, conversion of convertible bonds, or actions deemed necessary to protect corporate and shareholder value, subject to China Securities Regulatory Commission rules. • The Board will be authorised to formulate, amend, or terminate the repurchase scheme, establish securities accounts, and handle share cancellations and related filings.
Administrative details:
• Shareholders of H shares recorded by Tuesday, 16 June 2026, are eligible to attend and vote. The H-share register will be closed from Thursday, 11 June to Tuesday, 16 June 2026. • H-shareholders wishing to attend by proxy must lodge forms with Tricor Investor Services Limited by 24 hours before the meeting. • Travel and accommodation costs for attending the meeting are borne by shareholders.
Board composition includes Executive Directors Chen Yuqing (Chairman), Guan Xiaohui, Wen Deyong, Wang Kexin and Liu Yi; Non-Executive Directors Chen Qiyu and Pan Donghui; Independent Non-Executive Directors Yu Tze Shan Hailson, Wang Quandi, Chen Penghui and Yang Yucheng; and Employee Director Yan Jia.
Comments